Anagre Cap.
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Essential Thrombocythemia
Conditions
Essential Thrombocythemia
Trial Timeline
Jun 5, 2017 โ Dec 5, 2020
NCT ID
NCT03232177About Anagre Cap.
Anagre Cap. is a approved stage product being developed by Yuhan for Essential Thrombocythemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03232177. Target conditions include Essential Thrombocythemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03232177 | Approved | Completed |
Competing Products
20 competing products in Essential Thrombocythemia
Other Products from Yuhan
generic formulation of atorvastatin (Atorvaยฎ) + branded formulation of atorvastatin (Lipitorยฎ)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85